TipRanks
Eupraxia Pharmaceuticals (EPRX)
NASDAQ:EPRX
US Market
EPRX
Eupraxia Pharmaceuticals
RESEARCH TOOLSreports

Eupraxia Pharmaceuticals (EPRX) Income Statement

45 Followers

Eupraxia Pharmaceuticals Income Statement

Last quarter (Q2 2026), Eupraxia Pharmaceuticals's total revenue was C$0.00, a decrease of ― from the same quarter last year. In Q2, Eupraxia Pharmaceuticals's net income was C$-14.11M. See Eupraxia Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Mar 24Dec 22Dec 21
Total Revenue
$ 0.00$ 0.00$ 0.00C$ 0.00C$ 0.00
Gross Profit
$ -241.88K$ -163.47K$ -158.05KC$ -193.27KC$ -111.53K
Operating Expenses
$ 38.86M$ 25.54M$ 28.37MC$ 23.38MC$ 18.38M
Depreciation and Amortization
$ 241.88K$ 163.47K$ 158.05KC$ 193.27KC$ 111.53K
EBITDA
$ -38.86M$ -23.43M$ -28.16MC$ -22.14MC$ -21.96M
Operating Income
$ -39.11M$ -25.71M$ -28.53MC$ -23.58MC$ -18.47M
Other Income/Expenses
-$ 1.20M$ -1.08MC$ -341.08KC$ -4.90M
Pretax Income
$ -39.26M$ -24.51M$ -28.93MC$ -23.92MC$ -23.37M
Net Income
$ -39.25M$ -24.28M$ -28.15MC$ -23.26MC$ -22.99M
Per Share Metrics
Basic EPS
$ -1.05$ -0.72$ -1.19C$ -1.21C$ -1.61
Diluted EPS
$ -1.05$ -0.72$ -1.19C$ -1.21C$ -1.61
Weighted Average Shares Outstanding
 39.96M 33.93M 24.15M 19.29M 14.24M
Weighted Average Shares Outstanding (Diluted)
 39.96M 33.93M 24.15M 19.29M 14.24M

Eupraxia Pharmaceuticals Earnings and Revenue History